James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Here’s How Amazon.com, Inc. (AMZN) Bookstores Aren’t Actually Bookstores

Amazon.com (AMZN) doesn't likely see brick and mortar stores as profit centers. Still, they are a value-add for AMZN stock holders.

Don’t Sell Facebook Inc (FB) Stock Just Because It’s Losing the Teen Crowd

Facebook (FB) may not cater to the under-20 crowd too well, but that's something FB stock holders may want to celebrate rather than lament.

Why Ciena Corporation (CIEN), Dollar General Corp. (DG) and Campbell Soup Company (CPB) Are 3 of Today’s Worst Stocks

Campbell Soup Company (CPB), Ciena (CIEN) and Dollar General (DG) couldn't put a positive spin on their quarterly numbers on Thursday.

Why Otonomy Inc (OTIC), Dycom Industries, Inc. (DY) and Mondelez International Inc (MDLZ) Are 3 of Today’s Worst Stocks

Dycom Industries (DY), Mondelez International (MDLZ) and Otonomy (OTIC) investors had a pretty miserable Wednesday.

5 Stocks to Sell in September

History and circumstances don't bode well for these five companies, making them obvious stocks to sell before we get too far into September.